Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, contro... by Tricou, Vianney, Essink, Brandon, Ervin, John E, Turner, Mark, Escudero, Ian, Rauscher, Martina, Brose, Manja, Lefevre, Inge, Borkowski, Astrid, Wallace, Derek

Get full text

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience by Fernando, LakKumar, Kastner, Randee, Wickramasinghe, Pujitha, Fernando, Asvini D, Gunasekera, Dulanie, Nguyen, Van Hung, Liu, Mengya, LeFevre, Inge, Wallace, Derek, Folschweiller, Nicolas, Biswal, Shibadas

Get full text

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a... by Patel, Sanjay S., Winkle, Peter, Faccin, Alice, Nordio, Francesco, LeFevre, Inge, Galindo, Claudia

Get full text

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City by Biswal, Shibadas, Mendez Galvan, Jorge Fernando, Macias Parra, Mercedes, Galan-Herrera, Juan-Francisco, Carrascal Rodriguez, Monica Belisa, Rodriguez Bueno, Esteban Patricio, Brose, Manja, Rauscher, Martina, LeFevre, Inge, Wallace, Derek, Borkowski, Astrid

Get full text

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults by LeFevre, Inge, Bravo, Lulu, Folschweiller, Nicolas, Medina, Eduardo Lopez, Moreira, Edson Duarte, Nordio, Francesco, Sharma, Mayuri, Tharenos, Leslie M., Tricou, Vianney, Watanaveeradej, Veerachai, Winkle, Peter J., Biswal, Shibadas

Get full text

Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial by Espinoza, Felix, Tregnaghi, Miguel, Gentile, Angela, Abarca, Katia, Casellas, Javier, Collard, Alix, Lefevre, Inge, Jacquet, Jeanne-Marie

Get full text

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003) by Rivera, Luis, Biswal, Shibadas, Sáez-Llorens, Xavier, Reynales, Humberto, López-Medina, Eduardo, Borja-Tabora, Charissa, Bravo, Lulu, Sirivichayakul, Chukiat, Kosalaraksa, Pope, Martinez Vargas, Luis, Yu, Delia, Watanaveeradej, Veerachai, Espinoza, Felix, Dietze, Reynaldo, Fernando, LakKumar, Wickramasinghe, Pujitha, Duarte MoreiraJr, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, Venâncioda Cunha, Rivaldo, Rauscher, Martina, Zent, Olaf, Liu, Mengya, Hoffman, Elaine, LeFevre, Inge, Tricou, Vianney, Wallace, Derek, Alera, MariaTheresa, Borkowski, Astrid

Get full text

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial by Biswal, Shibadas, Borja-Tabora, Charissa, Martinez Vargas, Luis, Velásquez, Hector, Theresa Alera, Maria, Sierra, Victor, Johana Rodriguez-Arenales, Edith, Yu, Delia, Wickramasinghe, V Pujitha, Duarte Moreira, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Kosalaraksa, Pope, Espinoza, Felix, López-Medina, Eduardo, Bravo, Lulu, Tuboi, Suely, Hutagalung, Yanee, Garbes, Pedro, Escudero, Ian, Rauscher, Martina, Bizjajeva, Svetlana, LeFevre, Inge, Borkowski, Astrid, Saez-Llorens, Xavier, Wallace, Derek, Concepción, Alys, Villarreal, Ana Cecilia, Fernando, Asvini, Borja-Tabora, Charissa, Sirivichayakul, Chukiat, Yu, Delia, Gunasekera, Dulanie, López-Medina, Eduardo, Rodriguez-Arenales, Edith Johanna, Moreira, Edson Duarte, Espinoza, Felix, Velásquez, Hector, Reynales, Humberto, Luz, Kleber, Jimeno, Jose, Fernando, LakKumar, Bravo, Lulu, Vargas, Luis Martinez, Rivera, Luis, Alera, Maria Theresa, Manacharoen, Onanong, Lopez, Pio, Kosalaraksa, Pope, Wickramasinghe, V. Pujitha, Dietze, Reynaldo, da Cunha, Rivaldo Venâncio, Watanaveeradej, Veerachai, Sierra, Victor, Saez-Llorens, Xavier, Biswal, Shibadas, Brose, Manja, Rauscher, Martina, Bizjajeva, Svetlana, LeFevre, Inge, Borkowski, Astrid, Wallace, Derek, Escudero, Ian, Moss, Kelley, Garbes, Pedro, Meyer, Seetha, Hutagalung, Yanee, Tuboi, Suely, Tricou, Vianney

Get full text

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue by Sáez-Llorens, Xavier, Biswal, Shibadas, Borja-Tabora, Charissa, Fernando, LakKumar, Liu, Mengya, Wallace, Derek, Folschweiller, Nicolas, Reynales, Humberto, LeFevre, Inge

Get full text

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus... by Tricou, Vianney, Eyre, Susannah, Ramjee, Mahadev, Collini, Paul, Mojares, Zenaida, Loeliger, Edde, Mandaric, Sanja, Rauscher, Martina, Brose, Manja, Lefevre, Inge, Folschweiller, Nicolas, Wallace, Derek

Get full text

Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults by Tricou, Vianney, Winkle, Peter J., Tharenos, Leslie M., Rauscher, Martina, Escudero, Ian, Hoffman, Elaine, LeFevre, Inge, Borkowski, Astrid, Wallace, Derek

Get full text

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial by Tricou, Vianney, Sáez-Llorens, Xavier, Yu, Delia, Rivera, Luis, Jimeno, José, Villarreal, Ana Cecilia, Dato, Epiphany, Saldaña de Suman, Onix, Montenegro, Nathali, DeAntonio, Rodrigo, Mazara, Sonia, Vargas, Maria, Mendoza, Debbie, Rauscher, Martina, Brose, Manja, Lefevre, Inge, Tuboi, Suely, Borkowski, Astrid, Wallace, Derek

Get full text

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination by López-Medina, Eduardo, Biswal, Shibadas, Saez-Llorens, Xavier, Borja-Tabora, Charissa, Bravo, Lulu, Sirivichayakul, Chukiat, Vargas, Luis Martinez, Alera, Maria Theresa, Velásquez, Hector, Reynales, Humberto, Rivera, Luis, Watanaveeradej, Veerachai, Rodriguez-Arenales, Edith Johana, Yu, Delia, Espinoza, Felix, Dietze, Reynaldo, Fernando, Lak Kumar, Wickramasinghe, Pujitha, Duarte Moreira, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, da Cunha, Rivaldo Venâncio, Tricou, Vianney, Rauscher, Martina, Liu, Mengya, LeFevre, Inge, Wallace, Derek, Kosalaraksa, Pope, Borkowski, Astrid

Get full text

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination by Sirivichayakul, Chukiat, Biswal, Shibadas, Saez-Llorens, Xavier, López-Medina, Eduardo, Borja-Tabora, Charissa, Bravo, Lulu, Kosalaraksa, Pope, Alera, Maria Theresa, Reynales, Humberto, Rivera, Luis, Watanaveeradej, Veerachai, Yu, Delia, Espinoza, Felix, Dietze, Reynaldo, Fernando, LakKumar, Wickramasinghe, V Pujitha, Moreira, Jr, Edson Duarte, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, Venâncio da Cunha, Rivaldo, Oliveira, Ana Lucia, Rauscher, Martina, Fan, Huihao, Borkowski, Astrid, Escudero, Ian, Tuboi, Suely, Lloyd, Eric, Tricou, Vianney, Folschweiller, Nicolas, LeFevre, Inge, Vargas, Luis Martinez, Wallace, Derek

Get full text

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial by Tricou, Vianney, Yu, Delia, Reynales, Humberto, Biswal, Shibadas, Saez-Llorens, Xavier, Sirivichayakul, Chukiat, Lopez, Pio, Borja-Tabora, Charissa, Bravo, Lulu, Kosalaraksa, Pope, Vargas, Luis Martinez, Alera, Maria Theresa, Rivera, Luis, Watanaveeradej, Veerachai, Dietze, Reynaldo, Fernando, LakKumar, Wickramasinghe, V Pujitha, Moreira, Edson Duarte, Fernando, Asvini D, Gunasekera, Dulanie, Luz, Kleber, Oliveira, Ana Lucia, Tuboi, Suely, Escudero, Ian, Hutagalung, Yanee, Lloyd, Eric, Rauscher, Martina, Zent, Olaf, Folschweiller, Nicolas, LeFevre, Inge, Espinoza, Felix, Wallace, Derek

Get full text

2276. Immunogenicity of Takeda’s Bivalent Virus-Like Particle (VLP) Norovirus Vaccine (NoV) Candidate in Children From 6 Months up to 4 Years of Age by Masuda, Taisei, Lefevre, Inge, Mendelman, Paul, Sherwood, Jim, Bizjajeva, Svetlana, Borkowski, Astrid

Get full text

Antibody persistence six years after two doses of combined hepatitis A and B vaccine by Burgess, Margaret A, McIntyre, Peter B, Hellard, Margaret, Ruff, Tilman A, Lefevre, Inge, Bock, Hans L

Get full text

Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults by Van Damme, Pierre, von Sonnenburg, Frank, Hatz, Christoph, Hoet, Bernard, Lefevre, Inge, Leyssen, Maarten

Get full text

Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age by Poovorawan, Yong, Hutagalung, Yanee, Chongsrisawat, Voranush, Thaemboonlers, Apiradee, Lefevre, Inge

Get full text

The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: Results from four phase III multicenter trials across three continents by Ortega-Barrìa, Eduardo, Kanra, Güler, Leroux, Geert, Bravo, Lulu, Safary, Assad, Lefevre, Inge

Get full text